News

In the study 60% of patients treated with Amitiza experienced a spontaneous bowel movement within 24 hours of treatment, and 80% experienced a spontaneous bowel movement within 48

Replidyne submitted a new drug application in December 2005 for four indications including acute bacterial sinusitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis and uncomplicated skin and skin

In the trial patients with metabolic syndrome were treated with Qnexa and experienced a significant average weight loss and a reduction in waist circumference. Significant reductions were also

Results demonstrated that 6mg of Silenor was effective at inducing sleep and maintaining sleep throughout the night. There was a measured improvement of sleep time of 51 minutes

The interim analysis was triggered by the occurrence of 188 patient deaths. The results of the analysis will not be made available to the company until the study

Humira met the primary endpoint, which was the proportion of patients achieving clinical remission at week four compared to placebo. Data showed three times the percentage of patients

Coreg CR will utilize Flamel's Micropump technology, which controls the amounts of medicine in the body over a 24 hour period. This technology allows Coreg CR to be

Omnaris is an intranasal corticosteroid containing ciclesonide as active substance. It is indicated for the treatment in patients 12 years of age and older. In addition, the FDA

The approvable letter also outlined post-approval clinical requirements, which are consistent with recommendations made by the FDA advisory committee in August 2006. “We will request a meeting with